SRI-41315

SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity[1].

Product Specifications

CAS Number

[1613509-49-1]

UNSPSC

12352005

Target

CFTR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sri-41315.html

Purity

99.68

Solubility

DMSO : 20.83 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N(C)C(N=C(C3CCC3)N4C5=CC=CC=C5)=C1C4=O)C=CC=C2

Molecular Formula

C22H19N3O2

Molecular Weight

357.41

References & Citations

[1]Sharma J, et al. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun. 2021 Jul 16;12 (1) :4358.